Eli Lilly and Company $LLY Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 6.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 137,658 shares of the company’s stock after acquiring an additional 8,691 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Eli Lilly and Company were worth $147,938,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of LLY. Norges Bank acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $12,976,634,000. Capital Research Global Investors grew its stake in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the period. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares during the period. Amundi grew its stake in shares of Eli Lilly and Company by 27.1% during the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after purchasing an additional 964,675 shares during the period. Finally, Jennison Associates LLC grew its stake in shares of Eli Lilly and Company by 22.3% during the 4th quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock worth $5,517,059,000 after purchasing an additional 937,204 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LLY. Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Finally, Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research note on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,227.00.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly signed a collaboration and licensing deal with Ascidian Therapeutics worth up to $1.9 billion to develop RNA-based kidney-disease therapies, reinforcing its strategy of using GLP-1 cash flow to broaden the pipeline. Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
• Positive Sentiment: Management signaled that more M&A may be coming, which investors view as a way to reduce reliance on obesity drugs and build new long-term growth engines. Eli Lilly’s top dealmaker says don’t be surprised to see more M&A that pushes Lilly into new areas
• Positive Sentiment: Multiple articles highlighted Lilly as a stock to own, citing its strong GLP-1 franchise and broader pipeline momentum across gene editing, vaccines, and cancer. 3 Reasons Eli Lilly Remains a Buy
• Neutral Sentiment: Weight Watchers expanded access to its program through LillyDirect, which reinforces Lilly’s ecosystem around GLP-1 drugs but is not a direct financial catalyst on its own. Weight Watchers Expands Reach Through LillyDirect Partnership (WW)
• Neutral Sentiment: Technical/market commentary also turned favorable, with one note saying Lilly flashed two buy signals, adding to the bullish sentiment around the name. Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals
• Negative Sentiment: Broader market weakness from a selloff in AI/tech sentiment could create some cross-asset pressure, though this is not specific to Lilly’s fundamentals. Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,125.00 on Friday. The stock has a market cap of $1.06 trillion, a price-to-earnings ratio of 39.96, a PEG ratio of 1.18 and a beta of 0.53. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,149.10. The company’s 50-day moving average price is $970.24 and its 200 day moving average price is $1,012.19. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.